NCT05296564: Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers |
|
|
| Recruiting | 1/2 | 3 | RoW | CYCLOPHOSPHAMIDE and FLUDARABIN, CYTOXAN, Cyclophosphamide, HBI 0201-ESO TCRT, Aldesleukin, Interleukin-2 | Hadassah Medical Organization | Sarcoma, Synovial, Sarcoma,Soft Tissue, Melanoma Stage IV, Triple Negative Breast Cancer, Metastatic Cancer, Non Small Cell Lung Cancer, Bladder Urothelial Carcinoma, Neuroblastoma, Metastatic, Ovary Cancer | 12/27 | 12/27 | | |
